ADMA Q3 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$120M+78.1% YoY

Gross Profit

$60M49.8% margin

Operating Income

$40M33.1% margin

Net Income

$36M30.0% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

$25M

Free Cash Flow

$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$391M

Total Liabilities

$159M

Stockholders' Equity

$232M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120M	$67M	+78.1%
Gross Profit	$60M	$25M	+142.0%
Operating Income	$40M	$9M	+356.4%
Net Income	$36M	$3M	+1300.0%

Revenue Segments

ADMA BioManufacturing Segment

$113M94%

Plasma Collection Centers Segment

$7M6%

Corporate Segment

$36,0000%

Geographic Segments

United States

$115M96%

International

$5M4%